A compass for navigating the perils of hypertriglyceridaemia
- PMID: 33798463
- DOI: 10.1016/S2213-8587(21)00077-2
A compass for navigating the perils of hypertriglyceridaemia
Conflict of interest statement
GFW reports grants from Amgen, Regeneron, Sanofi, Novartis, and Arrowhead; and personal fees for advisory board membership from Amgen, Novartis, Arrowhead, AstraZeneca, and Esperion. NCW declares no competing interests.
Comment on
-
Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.Lancet Diabetes Endocrinol. 2021 May;9(5):264-275. doi: 10.1016/S2213-8587(21)00046-2. Epub 2021 Mar 30. Lancet Diabetes Endocrinol. 2021. PMID: 33798466 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
